The solid tumor cancer treatment market size has grown rapidly in recent years. It will grow from $265.41 billion in 2025 to $301.06 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to rising cancer incidence, chemotherapy adoption, radiation therapy advancements, oncology funding growth, early diagnosis improvements.
The solid tumor cancer treatment market size is expected to see rapid growth in the next few years. It will grow to $501.28 billion in 2030 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to immunotherapy approvals, targeted drug pipelines, personalized medicine adoption, oncology infrastructure expansion, survival rate improvements. Major trends in the forecast period include growth of checkpoint inhibitors, expansion of tumor-agnostic therapies, increased use of combination regimens, rising biomarker-driven treatment, outpatient oncology growth.
The rising incidence of cancer is expected to significantly drive the growth of the solid tumor cancer treatment market in the coming years. Cancer is a serious condition in which the body's cells grow rapidly and uncontrollably, resulting in abnormal tissue growth. Solid tumor cancer treatment involves therapies aimed at removing solid tumors from the bodies of cancer patients. For example, according to the World Health Organization, a Switzerland-based international public health organization, in 2022, nearly 20 million new cancer cases were reported globally, leading to approximately 10 million deaths. Demographic projections indicate that the annual incidence of cancer could rise to 35 million by 2050, representing a 77% increase from 2022. Lung cancer was the most frequently diagnosed type, with about 2.5 million new cases, accounting for one in every eight cancers worldwide, or 12.4% of all global cancers. Consequently, the rising incidence of cancer is fueling the growth of the solid tumor cancer treatment market.
Key players in the solid tumor cancer treatment market are concentrating on developing advanced immunotherapies, targeted therapies, and cell-based treatments to improve patient outcomes and expand treatment options. For instance, in July 2025, Dispatch Bio, a US-based biotechnology company, launched initiatives to develop universal therapies for solid tumors. The company aims to advance innovative therapeutic approaches that target a wide range of solid tumor types, enhance efficacy across diverse patient populations, and accelerate the development of scalable cancer immunotherapies, potentially transforming standard-of-care treatments and improving long-term survival rates.
In February 2024, AbbVie Inc., a US-based pharmaceutical company, acquired ImmunoGen, Inc. Through this acquisition, AbbVie seeks to strengthen its oncology capabilities by addressing unmet needs in cancer treatment. The company aims to enhance its solid tumor portfolio and expand its presence in the oncology market. ImmunoGen, Inc. is a US-based biotechnology firm that develops antibody-drug conjugate (ADC) therapeutics for cancer treatment.
Major companies operating in the solid tumor cancer treatment market are AstraZeneca plc, Amgen Inc., Bristol Myers Squibb & Company, Eli Lilly & Company, F Hoffmann La Roche Ltd, Merck & Co Inc, Novartis AG, Pfizer Inc, Olympus Medical Systems, Astellas Pharma Inc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd, Celldex Therapeutics Inc, AbbVie Inc, Bayer AG, Eisai Co Ltd, Exelixis Inc, Genentech Inc, Gilead Sciences Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Karyopharm Therapeutics Inc, Kyowa Kirin Co Ltd, MorphoSys AG, Regeneron Pharmaceuticals Inc, Sanofi SA, Seattle Genetics Inc, Spectrum Pharmaceuticals Inc, Taiho Pharmaceutical Co Ltd, Verastem Inc, Zymeworks Inc.
North America was the largest region in the solid tumor cancer treatment market in 2025. The regions covered in the solid tumor cancer treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the solid tumor cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the solid tumor cancer treatment market by increasing costs for imported oncology drugs, biologics, surgical instruments, and radiotherapy equipment. Hospitals and research institutes in Asia-Pacific and Europe are most impacted due to global sourcing of cancer therapeutics. These higher costs can slow the adoption of advanced immunotherapies and targeted therapies. However, tariffs are encouraging local production of cancer drugs and medical devices, improving long-term treatment security.
The solid tumor cancer treatment market research report is one of a series of new reports that provides solid tumor cancer treatment market statistics, including solid tumor cancer treatment industry global market size, regional shares, competitors with a solid tumor cancer treatment market share, detailed solid tumor cancer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the solid tumor cancer treatment industry. This solid tumor cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Solid tumor cancer treatment involves managing an abnormal mass of tissue that typically does not contain cysts or liquid-filled areas. Most of the tumor’s cells are produced by cancer stem cells through cell division. The goal of solid tumor cancer treatment is to improve patient outcomes by controlling disease progression, alleviating symptoms, enhancing quality of life, and increasing survival rates.
The main treatment options for solid tumor cancer include chemotherapy, targeted therapy, immunotherapy, hormone therapy, and surgical procedures. Chemotherapy involves the use of drugs to halt the division of cancer cells or kill them, preventing further proliferation. These treatments are applied to various cancers, including breast cancer, cervical cancer, colorectal cancer, lung cancer, prostate cancer, and others, and are utilized by end users such as hospitals, research institutes, and homecare providers.
The solid tumor cancer treatment market includes revenues earned by entities by treat solid tumor cancer through hormonal therapy, targeted drugs, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The solid tumor cancer treatment market size is expected to see rapid growth in the next few years. It will grow to $501.28 billion in 2030 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to immunotherapy approvals, targeted drug pipelines, personalized medicine adoption, oncology infrastructure expansion, survival rate improvements. Major trends in the forecast period include growth of checkpoint inhibitors, expansion of tumor-agnostic therapies, increased use of combination regimens, rising biomarker-driven treatment, outpatient oncology growth.
The rising incidence of cancer is expected to significantly drive the growth of the solid tumor cancer treatment market in the coming years. Cancer is a serious condition in which the body's cells grow rapidly and uncontrollably, resulting in abnormal tissue growth. Solid tumor cancer treatment involves therapies aimed at removing solid tumors from the bodies of cancer patients. For example, according to the World Health Organization, a Switzerland-based international public health organization, in 2022, nearly 20 million new cancer cases were reported globally, leading to approximately 10 million deaths. Demographic projections indicate that the annual incidence of cancer could rise to 35 million by 2050, representing a 77% increase from 2022. Lung cancer was the most frequently diagnosed type, with about 2.5 million new cases, accounting for one in every eight cancers worldwide, or 12.4% of all global cancers. Consequently, the rising incidence of cancer is fueling the growth of the solid tumor cancer treatment market.
Key players in the solid tumor cancer treatment market are concentrating on developing advanced immunotherapies, targeted therapies, and cell-based treatments to improve patient outcomes and expand treatment options. For instance, in July 2025, Dispatch Bio, a US-based biotechnology company, launched initiatives to develop universal therapies for solid tumors. The company aims to advance innovative therapeutic approaches that target a wide range of solid tumor types, enhance efficacy across diverse patient populations, and accelerate the development of scalable cancer immunotherapies, potentially transforming standard-of-care treatments and improving long-term survival rates.
In February 2024, AbbVie Inc., a US-based pharmaceutical company, acquired ImmunoGen, Inc. Through this acquisition, AbbVie seeks to strengthen its oncology capabilities by addressing unmet needs in cancer treatment. The company aims to enhance its solid tumor portfolio and expand its presence in the oncology market. ImmunoGen, Inc. is a US-based biotechnology firm that develops antibody-drug conjugate (ADC) therapeutics for cancer treatment.
Major companies operating in the solid tumor cancer treatment market are AstraZeneca plc, Amgen Inc., Bristol Myers Squibb & Company, Eli Lilly & Company, F Hoffmann La Roche Ltd, Merck & Co Inc, Novartis AG, Pfizer Inc, Olympus Medical Systems, Astellas Pharma Inc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd, Celldex Therapeutics Inc, AbbVie Inc, Bayer AG, Eisai Co Ltd, Exelixis Inc, Genentech Inc, Gilead Sciences Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Karyopharm Therapeutics Inc, Kyowa Kirin Co Ltd, MorphoSys AG, Regeneron Pharmaceuticals Inc, Sanofi SA, Seattle Genetics Inc, Spectrum Pharmaceuticals Inc, Taiho Pharmaceutical Co Ltd, Verastem Inc, Zymeworks Inc.
North America was the largest region in the solid tumor cancer treatment market in 2025. The regions covered in the solid tumor cancer treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the solid tumor cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the solid tumor cancer treatment market by increasing costs for imported oncology drugs, biologics, surgical instruments, and radiotherapy equipment. Hospitals and research institutes in Asia-Pacific and Europe are most impacted due to global sourcing of cancer therapeutics. These higher costs can slow the adoption of advanced immunotherapies and targeted therapies. However, tariffs are encouraging local production of cancer drugs and medical devices, improving long-term treatment security.
The solid tumor cancer treatment market research report is one of a series of new reports that provides solid tumor cancer treatment market statistics, including solid tumor cancer treatment industry global market size, regional shares, competitors with a solid tumor cancer treatment market share, detailed solid tumor cancer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the solid tumor cancer treatment industry. This solid tumor cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Solid tumor cancer treatment involves managing an abnormal mass of tissue that typically does not contain cysts or liquid-filled areas. Most of the tumor’s cells are produced by cancer stem cells through cell division. The goal of solid tumor cancer treatment is to improve patient outcomes by controlling disease progression, alleviating symptoms, enhancing quality of life, and increasing survival rates.
The main treatment options for solid tumor cancer include chemotherapy, targeted therapy, immunotherapy, hormone therapy, and surgical procedures. Chemotherapy involves the use of drugs to halt the division of cancer cells or kill them, preventing further proliferation. These treatments are applied to various cancers, including breast cancer, cervical cancer, colorectal cancer, lung cancer, prostate cancer, and others, and are utilized by end users such as hospitals, research institutes, and homecare providers.
The solid tumor cancer treatment market includes revenues earned by entities by treat solid tumor cancer through hormonal therapy, targeted drugs, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Solid Tumor Cancer Treatment Market Characteristics
3. Solid Tumor Cancer Treatment Market Supply Chain Analysis
4. Global Solid Tumor Cancer Treatment Market Trends and Strategies
5. Solid Tumor Cancer Treatment Market Analysis of End Use Industries
7. Global Solid Tumor Cancer Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Solid Tumor Cancer Treatment Total Addressable Market (TAM) Analysis for the Market
9. Solid Tumor Cancer Treatment Market Segmentation
10. Solid Tumor Cancer Treatment Market Regional and Country Analysis
11. Asia-Pacific Solid Tumor Cancer Treatment Market
12. China Solid Tumor Cancer Treatment Market
13. India Solid Tumor Cancer Treatment Market
14. Japan Solid Tumor Cancer Treatment Market
15. Australia Solid Tumor Cancer Treatment Market
16. Indonesia Solid Tumor Cancer Treatment Market
17. South Korea Solid Tumor Cancer Treatment Market
18. Taiwan Solid Tumor Cancer Treatment Market
19. South East Asia Solid Tumor Cancer Treatment Market
20. Western Europe Solid Tumor Cancer Treatment Market
21. UK Solid Tumor Cancer Treatment Market
22. Germany Solid Tumor Cancer Treatment Market
23. France Solid Tumor Cancer Treatment Market
24. Italy Solid Tumor Cancer Treatment Market
25. Spain Solid Tumor Cancer Treatment Market
26. Eastern Europe Solid Tumor Cancer Treatment Market
27. Russia Solid Tumor Cancer Treatment Market
28. North America Solid Tumor Cancer Treatment Market
29. USA Solid Tumor Cancer Treatment Market
30. Canada Solid Tumor Cancer Treatment Market
31. South America Solid Tumor Cancer Treatment Market
32. Brazil Solid Tumor Cancer Treatment Market
33. Middle East Solid Tumor Cancer Treatment Market
34. Africa Solid Tumor Cancer Treatment Market
36. Solid Tumor Cancer Treatment Market Competitive Landscape and Company Profiles
37. Solid Tumor Cancer Treatment Market Other Major and Innovative Companies
40. Solid Tumor Cancer Treatment Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Solid Tumor Cancer Treatment Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses solid tumor cancer treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for solid tumor cancer treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The solid tumor cancer treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Chemotherapy; Targeted Therapy; Immunotherapy; Hormone Therapy; Surgical Procedures2) By Application: Breast Cancer; Cervical Cancer; Colorectal Cancer; Lung Cancer; Prostate Cancer; Other Applications
3) By End-Users: Hospitals; Research Institutes; Homecare
Subsegments:
1) By Chemotherapy: Alkylating Agents; Antimetabolites; Anthracyclines; Mitotic Inhibitors2) By Targeted Therapy: Monoclonal Antibodies; Small Molecule Inhibitors; Signal Transduction Inhibitors
3) By Immunotherapy: Checkpoint Inhibitors; CAR T-Cell Therapy; Cancer Vaccines
4) By Hormone Therapy: Aromatase Inhibitors; Anti-Androgens; Selective Estrogen Receptor Modulators (SERMs)
5) By Surgical Procedures: Tumor Resection; Laparoscopic Surgery; Robotic-Assisted Surgery
Companies Mentioned: AstraZeneca plc; Amgen Inc.; Bristol Myers Squibb & Company; Eli Lilly & Company; F Hoffmann La Roche Ltd; Merck & Co Inc; Novartis AG; Pfizer Inc; Olympus Medical Systems; Astellas Pharma Inc; GlaxoSmithKline plc; Takeda Pharmaceutical Company Ltd; Celldex Therapeutics Inc; AbbVie Inc; Bayer AG; Eisai Co Ltd; Exelixis Inc; Genentech Inc; Gilead Sciences Inc; Incyte Corporation; Ipsen Biopharmaceuticals Inc; Karyopharm Therapeutics Inc; Kyowa Kirin Co Ltd; MorphoSys AG; Regeneron Pharmaceuticals Inc; Sanofi SA; Seattle Genetics Inc; Spectrum Pharmaceuticals Inc; Taiho Pharmaceutical Co Ltd; Verastem Inc; Zymeworks Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Solid Tumor Cancer Treatment market report include:- AstraZeneca plc
- Amgen Inc.
- Bristol Myers Squibb & Company
- Eli Lilly & Company
- F Hoffmann La Roche Ltd
- Merck & Co Inc
- Novartis AG
- Pfizer Inc
- Olympus Medical Systems
- Astellas Pharma Inc
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Ltd
- Celldex Therapeutics Inc
- AbbVie Inc
- Bayer AG
- Eisai Co Ltd
- Exelixis Inc
- Genentech Inc
- Gilead Sciences Inc
- Incyte Corporation
- Ipsen Biopharmaceuticals Inc
- Karyopharm Therapeutics Inc
- Kyowa Kirin Co Ltd
- MorphoSys AG
- Regeneron Pharmaceuticals Inc
- Sanofi SA
- Seattle Genetics Inc
- Spectrum Pharmaceuticals Inc
- Taiho Pharmaceutical Co Ltd
- Verastem Inc
- Zymeworks Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 301.06 Billion |
| Forecasted Market Value ( USD | $ 501.28 Billion |
| Compound Annual Growth Rate | 13.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 32 |
